Foreseen Biotechnology Ltd

Proteomics-driven target discovery for precision medicine

Foreseen Biotech is an emerging biotechnology company founded in 2021 by proteomics leader Catherine C.L. Wong, invested by leading investors including Sequoia China. The company established a proprietary, high-throughput proteomics, integrated multi-omics platforms and AI analytics to identify highly translatable novel disease targets. The company is building a diversified product pipeline with focus in oncology, inflammatory/immunological and CNS diseases.

News & Insights

Company news and publications.

View all updates
AACR

Abstract CT087: Phase I/II FIH study of IPN60300, a first-in-class ADC targeting ITGA2, to assess the safety, tolerability, PK, biomarkers, immunogenicity and antitumor activity in adults with locally advanced solid tumors

AACR published a clinical-trial abstract describing the ongoing Phase I/II first-in-human study of IPN60300, a first-in-class ADC targeting ITGA2, in adults with locally advanced solid tumors.

Source: aacrjournals.org
AACR

Abstract 1665: Preclinical characterization of IPN60300, a first-in-class ITGA2 antibody-drug conjugate for cancer therapy

AACR published a preclinical characterization abstract for IPN60300, an ITGA2-targeting antibody-drug conjugate for cancer therapy.

Source: aacrjournals.org
AACR

Abstract 4444: Integrin alpha-2 (ITGA2) is a novel and well-suited antibody-drug conjugate (ADC) target

AACR published an abstract describing ITGA2 as a novel and well-suited antibody-drug conjugate target and referencing IPN60300 in the ITGA2-targeted ADC context.

Source: aacrjournals.org
AACR

Abstract 7686: Identification of a first-in-class therapeutic target using machine learning enabled translational-optimized proteomics system (TPS)

AACR published an abstract describing TPS-enabled target identification and referencing FS001 / IPN60300.

Source: aacrjournals.org
Press Release

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for FS001

Foreseen granted Ipsen global development, manufacturing and commercialization rights for FS001, an ADC candidate with first-in-class potential.

Source: ipsen.com
Company

Building an upstream engine for novel target discovery

Foreseen’s platform strategy focuses on discovering highly differentiated targets at the source of drug and diagnostic innovation.

Platform

From clinical proteomics to translatable therapeutic targets

Integrated proteomics and AI analytics can help connect disease biology, biomarker discovery and therapeutic target validation.

Technology Platform

An integrated proteomics engine built for clinically relevant target discovery.

Single-cell and deep proteomics

High-sensitivity mass-spectrometry workflows are positioned to capture high-quality, high-depth and multi-dimensional proteomic information from clinical samples.

SurfSEEN® membrane-protein discovery

Foreseen’s membrane-protein toolkit supports the discovery of disease-relevant surface targets with stronger translational and therapeutic potential.

PrOmics® integrated omics system

PrOmics® combines internal data, multi-omics interpretation and AI-assisted analysis to prioritize mechanisms, biomarkers and novel targets.

Pipeline

Translating target biology into precision medicines.

Foreseen advances first-in-class therapeutics and novel biomarker programs through internal research and collaborations, with focus areas including oncology, autoimmune disease and rare diseases.

Candidate
Indication
Discovery
Lead optimization
IND enabling
Clinical development
Partnership
FS001IPN60300
Solid tumor
Phase I/II
Ipsen
FS002
Solid tumor
FS003
Solid tumor
FS008
Solid tumor
FS013
Solid tumor
FS015
Solid tumor
FS016
Solid tumor
Current progressDevelopment path

Company Profile

Delivering breakthrough precision medicine to improve patients’ lives.

Foreseen Biotech is an emerging biotechnology company founded in 2021 by proteomics leader Catherine C.L. Wong and backed by leading investors including Sequoia China.

The company established a proprietary platform to discover clinically relevant, highly translatable, novel targets for precision medicine. This target discovery engine comprises high-throughput proteomics, multi-omics platforms, AI analytics, and the company’s vast collection of well-characterized patient samples across multiple diseases. The target of FS001 (IPN60300), a first-in-class antibody-drug conjugate program, was discovered utilizing this platform.

Foreseen is advancing a product pipeline of therapeutic and diagnostic product candidates across multiple disease areas, including oncology, inflammatory and neurological diseases. The company executed its first worldwide license agreement for FS001 (IPN60300), at the preclinical development stage, with Ipsen in 2024 . This program is currently in a Phase I/II clinical trial in the US and Europe .

Contact

Partner with Foreseen.

For platform collaboration, therapeutics partnering, diagnostic translation, media or corporate inquiries, please share your contact information and collaboration focus. You can also reach us at contact@foreseen.bio.

Your message will be used only for follow-up related to this inquiry.